Response to peanut patch treatment increases through 60 months
Key takeaways:
- The VP250 VIASKIN Peanut patch includes 250 µg of peanut protein.
- Percentages of children who achieved a 1,000 mg eliciting dose increased.
- Levels of peanut-specific IgE and IgG4 levels decreased and increased.
SAN DIEGO — Percentages of children with peanut allergy who responded to treatment with the VP250 VIASKIN Peanut patch from DBV Technologies increased from 12 months through 60 months, according to an abstract presented here.
Treatment also was well tolerated, David Fleischer, MD, FAAAAI, section head of allergy and immunology, Children’s Hospital Colorado, said at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.
There are two products approved by the FDA for peanut allergy, Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp, Stallergenes Greer) oral immunotherapy and the anti-IgE biologic omalizumab (Xolair; Genentech, Novartis), Fleischer told Healio.
“OIT’s main limitations are safety — higher rates of anaphylaxis compared with VIASKIN and more restrictions with its use, ie, having to hold the dose while ill, restricting exercise close to dosing and the need for frequent up-dosing appointments,” he said.
“The major downside to Xolair is that it is an injectable medication, ie, a shot, and may be multiple shots every 2 to 4 weeks depending on the age and weight of the patient,” he continued, adding that these downsides may make these therapies less desirable for some patients.
The VP250 VIASKIN Peanut patch precludes these disadvantages, Fleischer said.
“It is an extremely safe product with low risk of anaphylaxis from it, and it is convenient and practical without the need for up-dosing and no restrictions with respect to illness or exercise,” he said.
The PEPITES study included 356 children aged 4 to 11 years who received VP250 or a placebo daily for 12 months. The VP250 VIASKIN Peanut patch includes 250 µg of peanut protein.
Next, 298 eligible participants (mean age, 11.1 years) enrolled in the PEPITES Open-Label Extension (PEOPLE), and 87 (29.2%) of these participants received VP250 through 60 months.
Percentages of children who responded to treatment increased from 39.1% at the end of PEPITES, or 12 months, to 52.9% at 36 months and 73.3% at the end of PEOPLE, or 60 months.
Also, percentages of children who achieved an eliciting dose of 1,000 mg or more, or the equivalent of three or four peanuts, increased from 33.3% at the end of PEPITES to 48.3% at 36 months and 66.7% at 60 months.
The researchers noted decreases in peanut-specific IgE levels and increases in peanut-specific IgG4 levels from baseline through 60 months that were consistent with other allergen immunotherapy and VP250 studies as well. Further, the researchers categorized the 93% mean treatment compliance through 5 years as high.
Based on these findings, the researchers concluded that long-term treatment with VP250 among children aged 4 to 11 years with peanut allergy yields accumulated benefits with high compliance.
“The data continue to show that VIASKIN can safely desensitize patients over time, with improvement in the amount of peanut tolerated with more years of wear time, reaching levels seen with other therapies,” Fleischer said.
Results from the phase 2 VITESSE trial, which will examine the efficacy of VP250 among children aged 4 to 7 years with peanut allergy, will be available in the fourth quarter.
“Two safety studies called COMFORT in 1- to 3-year-olds and in 4- to 7-year-olds will collect more safety data on VIASKIN as required by the FDA prior to hopeful FDA approval of it in 2026,” Fleischer said.
Reference:
- Log term use of peanut patch shows increased benefit over time. https://www.aaaai.org/about/news/news/2025/patch. Published Feb. 10, 2025. Accessed Feb. 10, 2025.